Guanosine triphosphate-15N5,d14 (dilithium)

CAT:
804-HY-113225S4
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Guanosine triphosphate-15N5,d14 (dilithium) - image 1

Guanosine triphosphate-15N5,d14 (dilithium)

  • UNSPSC Description:

    Guanosine triphosphate-15N5,d14 (GTP-15N5,d14) dilithium is deuterium and 15N labeled Guanosine triphosphate (HY-113225). Guanosine triphosphate is a native nucleotide. The derivatives of GTP may be used as specific inhibitors against COVID-19.
  • Target Antigen:

    DNA/RNA Synthesis; Endogenous Metabolite; Isotope-Labeled Compounds; Nucleoside Antimetabolite/Analog; SARS-CoV
  • Type:

    Isotope-Labeled Compounds
  • Related Pathways:

    Anti-infection;Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;Others
  • Applications:

    COVID-19-anti-virus
  • Field of Research:

    Cancer; Infection
  • Solubility:

    10 mM in DMSO
  • Smiles:

    O=P(O[2H])(O[Li])OP(OP(OC([2H])([2H])[C@@]1([2H])O[C@]([15N]2C([15N]=C([15N]([2H])[2H])[15N]([2H])C3=O)=C3[15N]=C2[2H])([2H])[C@](O[2H])([2H])[C@]1([2H])O[2H])(O[2H])=O)(O[Li])=O
  • Molecular Weight:

    554.10
  • References & Citations:

    [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Abdo A Elfiky, et al. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020 May 1;248:117477.
  • Shipping Conditions:

    Room temperature
  • Clinical Information:

    No Development Reported